↓ Skip to main content

Paraneoplastic neurological syndromes

Overview of attention for article published in Orphanet Journal of Rare Diseases, May 2007
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (97th percentile)
  • High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

news
3 news outlets
twitter
3 X users
patent
2 patents
wikipedia
18 Wikipedia pages

Citations

dimensions_citation
250 Dimensions

Readers on

mendeley
219 Mendeley
citeulike
1 CiteULike
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Paraneoplastic neurological syndromes
Published in
Orphanet Journal of Rare Diseases, May 2007
DOI 10.1186/1750-1172-2-22
Pubmed ID
Authors

Jérôme Honnorat, Jean-Christophe Antoine

Abstract

Paraneoplastic neurological syndromes (PNS) can be defined as remote effects of cancer that are not caused by the tumor and its metastasis, or by infection, ischemia or metabolic disruptions. PNS are rare, affecting less than 1/10,000 patients with cancer. Only the Lambert-Eaton myasthenic syndrome is relatively frequent, occurring in about 1% of patients with small cell lung cancer. PNS can affect any part of the central and peripheral nervous system, the neuromuscular junction, and muscle. They can be isolated or occur in association. In most patients, the neurological disorder develops before the cancer becomes clinically overt and the patient is referred to the neurologist who has the charge of identifying a neurological disorder as paraneoplastic. PNS are usually severely disabling. The most common PNS are Lambert-Eaton myasthenic syndrome (LEMS), subacute cerebellar ataxia, limbic encephalitis (LE), opsoclonus-myoclonus (OM), retinopathies (cancer-associated retinopathy (CAR) and melanoma-associated retinopathy (MAR), Stiff-Person syndrome (SPS), chronic gastrointestinal pseudoobstruction (CGP), sensory neuronopathy (SSN), encephalomyelitis (EM) and dermatomyositis. PNS are caused by autoimmune processes triggered by the cancer and directed against antigens common to both the cancer and the nervous system, designated as onconeural antigens. Due to their high specificity (> 90%), the best way to diagnose a neurological disorder as paraneoplastic is to identify one of the well-characterized anti-onconeural protein antibodies in the patient's serum. In addition, as these antibodies are associated with a restricted range of cancers, they can guide the search for the underlying tumor at a stage when it is frequently not clinically overt. This is a critical point as, to date, the best way to stabilize PNS is to treat the cancer as soon as possible. Unfortunately, about one-third of patients do not have detectable antibodies and 5% to 10% have an atypical antibody that is not well-characterized. As PNS are believed to be immune-mediated, suppression of the immune response represents another treatment approach.

X Demographics

X Demographics

The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 219 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Brazil 4 2%
Austria 1 <1%
Czechia 1 <1%
United Kingdom 1 <1%
Canada 1 <1%
Spain 1 <1%
Japan 1 <1%
United States 1 <1%
Poland 1 <1%
Other 0 0%
Unknown 207 95%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 30 14%
Other 29 13%
Researcher 26 12%
Student > Doctoral Student 21 10%
Student > Postgraduate 20 9%
Other 48 22%
Unknown 45 21%
Readers by discipline Count As %
Medicine and Dentistry 113 52%
Neuroscience 14 6%
Agricultural and Biological Sciences 8 4%
Nursing and Health Professions 4 2%
Biochemistry, Genetics and Molecular Biology 4 2%
Other 25 11%
Unknown 51 23%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 35. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 31 January 2024.
All research outputs
#1,140,574
of 25,270,999 outputs
Outputs from Orphanet Journal of Rare Diseases
#111
of 3,051 outputs
Outputs of similar age
#1,960
of 83,477 outputs
Outputs of similar age from Orphanet Journal of Rare Diseases
#1
of 15 outputs
Altmetric has tracked 25,270,999 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,051 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.2. This one has done particularly well, scoring higher than 96% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 83,477 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 15 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.